Zobrazeno 1 - 10
of 112
pro vyhledávání: ''
Publikováno v:
Pathology & Oncology Research. 26:2733-2745
Tumor immune microenvironment (TIME) is a significant prognostic parameter for triple negative breast carcinomas (TNBC) due to being a target for immunotherapeutic agents and its essential role during the cancer immunoediting process. In this study,
Autor:
Hans Heinzer, Sarah Minner, Markus Graefen, Doris Höflmayer, Sebastian Dwertmann Rico, Maria Christina Tsourlakis, Christoph Fraune, Claudia Hube-Magg, Jan Meiners, Christian Bernreuther, Till Eichenauer, Eike Burandt, Stefan Steurer, Ferdous Daghigh, Alexander Haese, Thorsten Schlomm, Katharina Möller, Guido Sauter, Jakob R. Izbicki, Andreas M. Luebke, David Dum, Maximilian Lennartz, Hartwig Huland, Christina Möller-Koop, Ronald Simon, Till S. Clauditz, Corinna Wittmer, Florian Lutz
Publikováno v:
Pathology Oncology Research
Secreted frizzled-related protein 4 (SFRP4) controls WNT signaling and is thought to play a role for tumor aggressiveness. Here, we analyzed a tissue microarray containing 11,152 prostate cancers with pathological, clinical and molecular data by immu
Publikováno v:
Pathology & Oncology Research. 26:2363-2370
High-grade neuroendocrine tumors (HGNET) have distinctive tumor biology/behaviour. Newer modalities of treatment (immunotherapy) for them have been included in recent NCCN guidelines. Detection of programmed death receptor-ligand 1 (PD-L1) expression
Autor:
Tomasz Rutkowski, Ewa Chmielik, Ewa Małusecka, Monika Giglok, Rafał Suwiński, Dariusz Lange, Agnieszka M. Mazurek
Publikováno v:
Pathology Oncology Research
Human papilloma virus (HPV) is highly frequent among patients with anal squamous cell carcinoma, but the viral load (VL) differs between patients. This study aimed to compare the rate of HPV positivity, HPV16VL, p16INK4A and p53 expression between tr
Autor:
Tímea Szekerczés, Katalin Borka, Gábor Lendvai, Zsuzsa Schaff, Gógl A, András Kiss, Ildikó Illyés, Klára Werling, József Mandl
Publikováno v:
Pathology Oncology Research
Although the role of autophagy has been implicated in several forms of chronic hepatitis, it is still not fully understood. Active autophagy eliminates damaged molecules and organelles (such as mitochondria) by lysosomal degradation. In the present s
Autor:
Erzsébet Rásó, Zoltán Sápi, Béla Iványi, Janina Kulka, Levente Kuthi, Brigitta Vrabély, Alex Jenei, Zoltán Bajory, Tamás Micsik, Áron Somorácz, Adrienn Hajdu
Publikováno v:
Pathology Oncology Research
Thirty-one cases of low-grade renal cell carcinoma (RCC) with clear cells and tubulopapillary/papillary architecture were analyzed retrospectively with immunohistochemical and genetic markers to gain more experience with the differential diagnosis of
Publikováno v:
Pathology & Oncology Research. 26:1559-1564
Clear cell odontogenic carcinoma (CCOC) is a rare odontogenic tumor associated with aggressive clinical behavior, metastasis and low survival. To date, only 67 cases have been described in the English language literature, and an understanding of the
Autor:
Michaela Bártů, Barbora Boudova, Ivana Tichá, Jan Laco, Kristýna Němejcová, Mára M, Pavel Dundr, Jan Hojný, Lukáš Krbal, Mária Gregová
Publikováno v:
Pathology & Oncology Research. 26:1527-1537
Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological
Autor:
Janina Kulka, Béla Molnár, Tibor Krenács, Anna-Mária Tőkés, Magdolna Dank, Dorottya Mühl, Gyöngyvér Szentmártoni, Tímea Tőkés, Gergő Kiszner
Publikováno v:
Pathology Oncology Research
We aimed to analyze the expression of cell-cycle regulation markers – minichromosome maintenance protein 2 (MCM2), Ki-67, Cyclin-A and phosphohistone-H3 (PHH3) − in pre-treatment core-biopsy samples of breast carcinomas in correlation with known
Publikováno v:
Pathology & Oncology Research. 26:1447-1450
Neuroendocrine cancer of the prostate is considered to be a rare entity with bad prognosis and limited therapeutic options. We performed a prospective analysis of the patients treated in our hospital for prostate cancer between 1st January 2015 and 3